192 related articles for article (PubMed ID: 18245552)
1. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
[TBL] [Abstract][Full Text] [Related]
3. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
[TBL] [Abstract][Full Text] [Related]
6. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
[TBL] [Abstract][Full Text] [Related]
7. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
Barth RF; Wu G; Yang W; Binns PJ; Riley KJ; Patel H; Coderre JA; Tjarks W; Bandyopadhyaya AK; Thirumamagal BT; Ciesielski MJ; Fenstermaker RA
Appl Radiat Isot; 2004 Nov; 61(5):899-903. PubMed ID: 15308165
[TBL] [Abstract][Full Text] [Related]
8. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors.
Yang W; Barth RF; Adams DM; Soloway AH
Cancer Res; 1997 Oct; 57(19):4333-9. PubMed ID: 9331095
[TBL] [Abstract][Full Text] [Related]
10. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
Yang W; Barth RF; Wu G; Huo T; Tjarks W; Ciesielski M; Fenstermaker RA; Ross BD; Wikstrand CJ; Riley KJ; Binns PJ
J Neurooncol; 2009 Dec; 95(3):355-365. PubMed ID: 19588228
[TBL] [Abstract][Full Text] [Related]
11. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
[TBL] [Abstract][Full Text] [Related]
12. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
14. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
[TBL] [Abstract][Full Text] [Related]
16. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
17. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors.
Capala J; Barth RF; Bendayan M; Lauzon M; Adams DM; Soloway AH; Fenstermaker RA; Carlsson J
Bioconjug Chem; 1996; 7(1):7-15. PubMed ID: 8741985
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
[TBL] [Abstract][Full Text] [Related]
19. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.
Barth RF; Yang W; Al-Madhoun AS; Johnsamuel J; Byun Y; Chandra S; Smith DR; Tjarks W; Eriksson S
Cancer Res; 2004 Sep; 64(17):6287-95. PubMed ID: 15342417
[TBL] [Abstract][Full Text] [Related]
20. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model.
Ozawa T; Afzal J; Lamborn KR; Bollen AW; Bauer WF; Koo MS; Kahl SB; Deen DF
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):247-52. PubMed ID: 16111595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
